The EPS projection of Pharmerica Corporation (NYSE:PMC) for quarter ended 2016-09-30 is $0.52. Last week, the projection for EPS was $0.52 against target of $0.52, a month earlier. While 2-months ago, this projection was $0.52 versus forecast of $0.52a quarter months earlier, posting a deviation of 0%.
Pharmerica Corporation (NYSE:PMC) posted that 18 days earlier, the share price was revised 1 times on upside. In addition, negative revisions were 1.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 2, and 2, correspondingly.
The per-share earnings downgrade for Pharmerica Corporation (NYSE:PMC) in the preceding 30 and 120 were 0 and 0. While in 60 and 90 days were 0, and 0, in that order.
Pharmerica Corporation (NYSE:PMC) EPS target was $0.52 for the quarter closed 1. It was based on 2 calls. As on 2016-05-06 the EPS was $0.45. The change was $0.08, posting a deviation of 21.62%. The price projections gave a standard deviation of 0.01.
Quarterly Sales Estimates
Pharmerica Corporation (NYSE:PMC) sales prediction for the fiscal 2016 stands at $542.75 and the median estimate is at $542.75. Almost 2 analysts gave sales target.
Among this, the highest sales estimate is $550 while the lowest target is $535.5 showing standard deviation of 10.253%.
As many as 2 analysts have positive sales targets revision while 2 reduced sales estimates, posting a deviation of 0%.
Last month, 2 experts have positive sales number revision. Also, 2 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast, posting a deviation of -1.354%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...